Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.48 |
| ▸ | CCR7 | P32248 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604863 | 0.85 | CXCR2 (0.49) | CXCR2CHRM5CX3CR1CCR7 | |
| SCHEMBL3613948 | 0.83 | CXCR2 (0.62) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3607547 | 0.81 | CXCR2 (0.63) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3599667 | 0.81 | CXCR2 (0.63) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3607723 | 0.80 | CXCR2 (0.62) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3605166 | 0.80 | CXCR2 (0.59) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3611217 | 0.78 | CXCR2 (0.49) | CXCR2CHRM5CX3CR1CCR7 | |
| SCHEMBL3599639 | 0.78 | CXCR2 (0.61) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3606631 | 0.78 | CXCR2 (0.61) | CXCR2CHRM5CX3CR1CCR7 | |
| SCHEMBL3614058 | 0.78 | CXCR2 (0.61) | CXCR2CHRM5CX3CR1CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | claimed |
| EP-2086947-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008061740-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| EP-2086947-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008061740-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063080-A1 | CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885CHRM5 4122/4885CX3CR1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.